About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2013 (2013), Article ID 981684, 12 pages
http://dx.doi.org/10.1155/2013/981684
Review Article

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

1Division of Medical Oncology, University of UT Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA
2Department of Internal Medicine, University of UT, Salt Lake City, Utah 84112, USA
3Department of Pathology and ARUP Laboratories, University of UT, Salt Lake City, Utah 84108, USA

Received 31 January 2013; Accepted 10 April 2013

Academic Editor: William L. Dahut

Copyright © 2013 Jesal C. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics,” A Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar
  2. Y. Chen, N. J. Clegg, and H. I. Scher, “Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target,” The Lancet Oncology, vol. 10, no. 10, pp. 981–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. H. M. Reid, G. Attard, E. Barrie, and J. S. de Bono, “CYP17 inhibition as a hormonal strategy for prostate cancer,” Nature Clinical Practice Urology, vol. 5, no. 11, pp. 610–620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Edwards, N. S. Krishna, K. M. Grigor, and J. M. S. Bartlett, “Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer,” British Journal of Cancer, vol. 89, no. 3, pp. 552–556, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Steinkamp, O. A. O'Mahony, M. Brogley et al., “Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy,” Cancer Research, vol. 69, no. 10, pp. 4434–4442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Agarwal, T. E. Hutson, N. J. Vogelzang, and G. Sonpavde, “Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer,” Future Oncology, vol. 6, no. 5, pp. 665–679, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. de Bono, C. J. Logothetis, A. Molina, et al., “Abiraterone and increased survival in metastatic prostate cancer.,” The New England Journal of Medicine, vol. 364, no. 21, pp. 1995–2005, 2011. View at Publisher · View at Google Scholar
  8. C. J. Ryan, M. R. Smith, J. S. de Bono, et al., “Abiraterone in metastatic prostate cancer without previous chemotherapy,” The New England Journal of Medicine, vol. 368, no. 2, pp. 138–148, 2013. View at Publisher · View at Google Scholar
  9. D. B. Agus, W. M. Stadler, D. H. Shevrin et al., “Efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study,” Journal of Clinical Oncology, vol. 30, no. 5, supplement 98, 2012.
  10. M. Hussain, P. Corn, D. Michaelson et al., “Activity and safety of the investigational agent orteronel in men with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen: results of a phase 2 study,” in Proceedings of the 27th Annual European Association of Urology, pp. 24–28, Paris, France, February 2012.
  11. C. Tran, “Development of a second-generation antiandrogen for treatment of advanced prostate cancer,” Science, vol. 324, no. 5928, pp. 787–790, 2009. View at Publisher · View at Google Scholar
  12. H. I. Scher, K. Fizazi, F. Saad, et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012. View at Publisher · View at Google Scholar
  13. D. E. Rathkopf, D. C. Danila, M. J. Morris et al., “Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): phase I results of a prostate cancer clinical trials consortium study,” Journal of Clinical Oncology, vol. 30, 5, 2012.
  14. M. R. Smith, E. S. Antonarakis, C. J. Ryan, et al., “ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC),” ASCO Meeting Abstracts, vol. 31, 6, 2013.
  15. D. E. Rathkopf, E. S. Antonarakis, N. D. Shore, et al., “ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC),” ASCO Meeting Abstracts, vol. 31, 6, 2013.
  16. T. Vasaitis, A. Belosay, A. Schayowitz et al., “Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H- benzimidazole-1-yl)androsta-5,16-diene in prostate cancer,” Molecular Cancer Therapeutics, vol. 7, no. 8, pp. 2348–2357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Zhang, S. Castaneda, M. Dumble, et al., “Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2309–2319, 2011. View at Publisher · View at Google Scholar
  18. R. J. Andersen, N. R. Mawji, J. Wang et al., “Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor,” Cancer Cell, vol. 17, no. 6, pp. 535–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Summy and G. E. Gallick, “Src family kinases in tumor progression and metastasis,” Cancer and Metastasis Reviews, vol. 22, no. 4, pp. 337–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Fizazi, “The role of Src in prostate cancer,” Annals of Oncology, vol. 18, no. 11, pp. 1765–1773, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Araujo, G. C. Trudel, F. Saad, et al., “Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial,” ASCO Meeting Abstracts, vol. 31, 6, 2013.
  22. M. Karlou, V. Tzelepi, and E. Efstathiou, “Therapeutic targeting of the prostate cancer microenvironment,” Nature Reviews Urology, vol. 7, no. 9, pp. 494–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. S. Antonarakis, M. A. Carducci, and M. A. Eisenberger, “Novel targeted therapeutics for metastatic castration-resistant prostate cancer,” Cancer Letters, vol. 291, no. 1, pp. 1–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Duran, C. Montagut, E. Calvo et al., “Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): a phase I/II trial of the combination of temsirolimus and docetaxel,” Journal of Clinical Oncology, vol. 30, 5, 2012.
  25. W. D. Figg, P. Arlen, J. Gulley et al., “A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer,” Seminars in Oncology, vol. 28, no. 4, pp. 62–66, 2001. View at Scopus
  26. W. L. Dahut, J. L. Gulley, P. M. Arlen et al., “Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer,” Journal of Clinical Oncology, vol. 22, no. 13, pp. 2532–2539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. W. D. Figg, H. Li, T. Sissung et al., “Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer,” BJU International, vol. 99, no. 5, pp. 1047–1055, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. R. Molife, P. C. Fong, L. Paccagnella et al., “The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study,” British Journal of Cancer, vol. 103, no. 3, pp. 332–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. S. Higano, J. J. Alumkal, C. J. Ryan et al., “A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): feasibility of every 3-week dosing and updated results,” Genitourinary Cancers Symposium, vol. 189, 2010.
  30. C. N. Sternberg, H. Dumez, H. Van Poppel et al., “Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer,” Annals of Oncology, vol. 20, no. 7, pp. 1264–1269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Anai, S. Goodison, K. Shiverick, Y. Hirao, B. D. Brown, and C. J. Rosser, “Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts,” Molecular Cancer Therapeutics, vol. 6, no. 1, pp. 101–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Liu, W. K. Kelly, G. Wilding, L. Leopold, K. Brill, and B. Somer, “An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer,” Clinical Cancer Research, vol. 15, no. 9, pp. 3172–3176, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Sonpavde, V. Matveev, J. M. Burke, et al., “Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer,” Annals of Oncology, vol. 23, no. 7, pp. 1803–1808, 2012. View at Publisher · View at Google Scholar
  34. K. N. Chi, S. J. Hotte, E. Y. Yu et al., “Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4247–4254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Zoubeidi, K. Chi, and M. Gleave, “Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer,” Clinical Cancer Research, vol. 16, no. 4, pp. 1088–1093, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Stavridi, E. M. Karapanagiotou, and K. N. Syrigos, “Targeted therapeutic approaches for hormone-refractory prostate cancer,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 122–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. W. K. You and D. M. M, “The hepatocyte growth factor/c-met signaling pathway as a therapeutic target to inhibit angiogenesis,” Journal of Biochemistry and Molecular Biology, vol. 41, no. 12, pp. 833–839, 2008. View at Scopus
  38. W. H. Tu, C. Zhu, C. Clark, J. G. Christensen, and Z. Sun, “Efficacy of c-Met inhibitor for advanced prostate cancer,” BMC Cancer, vol. 10, article 556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. D. C. Smith, M. R. Smith, C. Sweeney, et al., “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial,” Journal of clinical oncology, vol. 31, no. 4, pp. 412–419, 2012. View at Publisher · View at Google Scholar
  40. D. N. Lavery and C. L. Bevan, “Androgen receptor signalling in prostate cancer: the functional consequences of acetylation,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 862125, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Bradley, D. Rathkopf, R. Dunn et al., “Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the department of defense prostate cancer clinical Trial consortium and university of chicago phase 2 consortium,” Cancer, vol. 115, no. 23, pp. 5541–5549, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Rathkopf, B. Y. Wong, R. W. Ross et al., “A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 1, pp. 181–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Sonpavde, A. M. Aparicio, F. Zhan, et al., “Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer,” Urologic Oncology, vol. 29, no. 6, pp. 682–689, 2011. View at Publisher · View at Google Scholar
  44. K. Fizazi, M. Carducci, M. Smith et al., “Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study,” The Lancet, vol. 377, no. 9768, pp. 813–822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Saad, D. M. Gleason, R. Murray et al., “Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer,” Journal of the National Cancer Institute, vol. 96, no. 11, pp. 879–882, 2004. View at Scopus
  46. A. O. Sartor, D. Heinrich, S. I. Helle et al., et al., “Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA),” Journal of Clinical Oncology, vol. 30, 5, 2012.
  47. N. Agarwal, N. Vogelzang, and N. J, Development of Novel Immune Interventions For Genito-Urinary Cancers. Cancer Vaccines, Adrian Bot, Mihail Obrocea & Francesco Marincola, Informa Healthcare, London, UK, 2011.
  48. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. L. G. Gomella, C. Nabhan, T. DeVries, J. B. Whitmore, M. W. Frohlich, and D. J. George, “Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cryopreserved cells,” in American Urological Association Annual Meeting (AUA '12), 2012.
  50. J. Schlom, M. Vergati, C. Intrivici, N. Y. Huen, and K. Y. Tsang, “Strategies for cancer vaccine development,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 596432, 13 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Sonpavde, K. M. Slawin, D. M. Spencer, and J. M. Levitt, “Emerging vaccine therapy approaches for prostate cancer,” Reviews in Urology, vol. 12, no. 1, pp. 25–34, 2010.
  52. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. L. F. Langer, T. M. Clay, and M. A. Morse, “Update on anti-CTLA-4 antibodies in clinical trials,” Expert Opinion on Biological Therapy, vol. 7, no. 8, pp. 1245–1256, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. D. O'Mahony, J. C. Morris, C. Quinn et al., “A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy,” Clinical Cancer Research, vol. 13, no. 3, pp. 958–964, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. S. T. Tagawa, H. Beltran, S. Vallabhajosula et al., “Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer,” Cancer, vol. 116, no. 4, pp. 1075–1083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. N. H. Bander, D. M. Nanus, M. I. Milowsky, L. Kostakoglu, S. Vallabahajosula, and S. J. Goldsmith, “Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen,” Seminars in Oncology, vol. 30, no. 5, pp. 667–677, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. J. T. Isaacs, “The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer,” Expert Opinion on Investigational Drugs, vol. 19, no. 10, pp. 1235–1243, 2010. View at Publisher · View at Google Scholar · View at Scopus